Press & news

Biofidelity, a revolutionary genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world, today announced the commercial launch of ASPYRE®-Lung in the US.

ASPYRE simplifies and accelerates the detection of actionable biomarkers in both DNA and RNA from either tissue or plasma within two days.

Biofidelity has expanded its Board of Directors to include Matt Franklin, MBA, who will join as a Non-Executive Director.

Barnaby Balmforth, CEO of Biofidelity receives the Life Science Innovation Award from AstraZeneca’s Shaun Grady and Sir Greg Winter.

Biofidelity, a British genomic technology company with U.S. headquarters in Morrisville, has commercially launched a novel assay to guide the treatment of non-small cell lung cancer in U.S. patients. The assay, called ASPYRE-Lung, simplifies and accelerates the detection of biomarkers for lung cancer, enabling clinicians to determine which treatment is best for each patient at a lower cost than current RNA and DNA sequencing tests, and in days instead of weeks, the company said in a news release.

Lung cancer is the leading cause of cancer deaths in the US, with more than 200,000 cases diagnosed every year, according to a Biofidelity press release from Tuesday. And while targeted treatments can offer big benefits to lung cancer patients, the company says that 65% of lung cancer patients start treatment without them.